Cancer Nanotechnology Platform Partnerships (CNPPs)
The CNPPs engage in directed, product-focused research that aims to translate cutting-edge science and technology into the next generation of diagnostic and therapeutic tools. These platforms serve as the core technologies for a wide array of specific applications that will ultimately benefit cancer patients.
CNPPs are designed to enable multi-disciplinary team research and transformative discoveries in basic and pre-clinical cancer research. The proposed individual, circumscribed research projects are expected to address major barriers and fundamental questions in cancer biology, diagnosis, prevention and treatment of the disease using innovative nanotechnology solutions. To advance such new nanotechnology discoveries, the platform projects take advantage of the collaborative environment of the Alliance network.
The awarded programs are listed below:
Combinatorial-designed Nano-platforms to Overcome Tumor Resistance
Principal Investigators: Mansoor Amiji, Ph.D., and Zhen-feng Duan, M.D., Ph.D.
High-Capacity Nanocarriers for Cancer Therapeutics
University of North Carolina at Chapel Hill
Principal Investigator: Alexander Kabanov, Ph.D, D.Sc.
Magnetoresistive Sensor Platform for Parallel Cancer Marker Detection
University of Utah
Principal Investigators: Marc Porter, Ph.D., and Sean J. Mulvihill, M.D.
Nanobioconjugate Based on Polymalic Acid for Brain Tumor Treatment
Cedars-Sinai Medical Center
Principal Investigator: Julia Ljubimova, M.D., Ph.D.
Nanoscale Metal-Organic Frameworks for Imaging and Therapy of Pancreatic Cancer
University of Chicago/University of North Carolina at Chapel Hill
Principal Investigators: Wenbin Lin, Ph.D., and Jen Jen Yeh, M.D.
Peptide-Directed Protocells and Virus-like Particles: New Nanoparticle Platforms for Targeted Cellular Delivery of Multicomponent Cargo
University of New Mexico
Principal Investigators: Cheryl Willman, M.D., and C. Jeffrey Brinker, Ph.D.
Preclinical Platform for Theranostic Nanoparticles in Pancreatic Cancer
Principal Investigators: Naomi Halas, Ph.D., D.Sc., Amit Joshi, Ph.D., and Sunil Krishnan, M.D.
Targeting SKY Kinase in B-Lineage ALL with CD-19 Specific C-61 Nanoparticles
Children’s Hospital Los Angeles
Principal Investigator: Fatih Uckun, M.D., Ph.D.
Theranostic Nanoparticles for Targeted Treatment of Pancreatic Cancer
Principal Investigators: Lily Yang, M.D., Ph.D., and Hui Mao, Ph.D.
Toxicity and Efficacy of Gold Nanoparticle Photothermal Therapy in Cancer
Principal Investigators: Dong Shin, M.D., and Mostafa El-Sayed, Ph.D.
Tumor Targeted Nanobins for the Treatment of Metastatic Breast and Ovarian Cancer
Principal Investigators: Thomas O'Halloran, Ph.D., and Vincent Cryns, M.D.